Case study

How Alphagenix generated 3.6 million views and 100+ enquiries in a taboo category

Alphagenix came to us to reshape how TRT is talked about. A founder-led LinkedIn strategy generated 3.6 million views, 21,000 followers and more than 100 qualified enquiries.

Headline figures

3.6M

Views generated across organic content

100+

Inbound enquiries from high-quality prospects

21K

Followers grown on founder's LinkedIn profile

Just this year alone they've helped us gain nearly 2 million impressions on LinkedIn as well as getting regular enquiries in the inbox. Highly recommend.

About Alphagenix

What they do

Specialist TRT therapy provider

Industry

Healthcare

Headquarters

United Kingdom

Engagement

Content, Strategy

TL;DR

Alphagenix offers specialist TRT therapy to men across the UK. Growth and clinical results were strong; public perception was the barrier. noticed. built a founder-led content strategy that took the subject head on.

• Reach: 3.6 million views and 21,000 followers on the founder's profile.
• Commercial: 100+ qualified inbound enquiries, through a channel that now brings prospects in directly.
• Method: answering the objections people were too awkward to ask.

Challenge

The barrier was not awareness. It was suspicion.

Most people did not understand what TRT was, or viewed it with scepticism. Alphagenix did not just want visibility — they wanted to move the category from taboo to understood, which is a harder and more valuable job.

Visibility in a misunderstood category makes the misunderstanding more widespread. The education has to come first or the reach works against you.

Taking the objection head on

Answering the questions people were too awkward to ask.

The content explained the science plainly and addressed the scepticism directly rather than working around it. In a category with a credibility problem, the objection is the content — anything that avoids it reads as the avoidance it is.

• Plain explanation over clinical register, because clarity beats clever, and a prospect who does not follow the argument does not act on it.
• The founder as the named voice, since a person can say things credibly that a clinic brand cannot.
• Consistency long enough to become the reference, so that the founder became the recognisable voice in the space rather than one provider among many.

Why the founder, not the clinic

A person can say things credibly that a provider cannot.

A clinic publishing about TRT reads as a clinic selling TRT, and in a category people already treat with suspicion that is the worst possible register. The same argument from a named founder reads as someone explaining their field.

Engagement also travels through human networks rather than brand pages, so the founder-led route was both the more credible and the further-reaching option. Sustained long enough, it made him the recognisable voice in the space rather than one provider among many — which is the position that generates inbound without asking for it.

Results

A reframing of how the category was discussed, with a direct commercial channel behind it.

Reach

3.6 million views generated across organic content.

Enquiries

More than 100 inbound enquiries from high-quality prospects.

Audience

21,000 followers grown on the founder's profile.